secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001193125-26-059334
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel secures $100M royalty funding from RTW for CAN-2409 prostate cancer launch; prelim cash $119.7M
--------------------------------------------------------------------------------

- Candel enters $100M royalty funding deal with RTW; funds available upon FDA approval of CAN-2409 for localized prostate cancer.
- RTW receives 4.67% royalty on US net sales ≤$1B, 1.33% above $1B; cap at $250M; ratchet to 6.67% if sales miss targets.
- Preliminary cash and equivalents ~$119.7M as of Dec 31, 2025 (unaudited).
- BLA submission for CAN-2409 in localized prostate cancer remains on track for Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526059334/0001193125-26-059334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526059334/cadl-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-059334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer